

Institut für seltene Erkrankungen in der Hämatologie

Leitung: Univ.-Prof. Dr. Paul Knöbl

Medizinische Universität Wien, Innere Medizin 1, Lazarettgasse 25/1. Stock, 1090 Wien

E-Mail: p.knoebl@karl-landsteiner.at

Referate

- ASH 2023, San Diego: Poster: Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange: Analysis of Efficacy and Safety Data by Lucas Kühne, Paul Knöbl, Kathrin Eller, Paul T. Brinkkötter, Linus A. Völker
- Euroanesthesia Glasgow 2023: P.Knöbl: Management of patients with thrombotic microangiopathies in the ICU.
- ISTH Montreal 2023: L. Kühne: Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
- Fortbildung Innsbruck: P.Knöbl: Update zur TTP
- Wiener Bluttag: P.Knöbl: Vaccine-induced thrombotic thrombocytopenia

Publikationen

- Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group. Pfrepper C, et al. *Hamostaseologie*. 2023 Dec 4. doi: 10.1055/a-2197-9738.
- Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study. Tiede A, Hart C, Knöbl P, et al. *Lancet Haematol*. 2023 Nov;10(11):e913-e921. doi: 10.1016/S2352-3026(23)00280-6.
- Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. Völker LA, et al.; German TTP-Study Group. *J Thromb Haemost*. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010.
- N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. Graf I, et al. *Am J Hematol*. 2023 Feb;98(2):290-299. doi: 10.1002/ajh.26805.
- Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis. Gelbenegger G, Traby L, Rahimi N, Knöbl P. *Br J Clin Pharmacol*. 2023 Feb;89(2):908-913. doi: 10.1111/bcp.15598.
- Safer steps on a narrow path. Knoebl P. *Blood*. 2022 Nov 3;140(18):1923-1924. doi: 10.1182/blood.2022017947.